The stock prices can overshoot to the downside or upside in major way especially when investing in this neck of the woods. Clinical trials are moving along as is expansion , EU MDR approval is expected by about September this year. TGA considers that data in the application for regulatory approval in Australia as the TGA takes EU MDR approval seriously. FDA approval process is moving along.
The main play here imo is that this is being primed for a take over with a larger pharma who can monetize this device much better than Oncosil can . I think Oncosil know this. Bullish changes to T20 , institutional placement , larger investors buying and others increasing holdings could assist a much better deal for investors.
- Forums
- ASX - By Stock
- OSL
- Ann: Australian institution to invest $2.7 million in OSL
Ann: Australian institution to invest $2.7 million in OSL, page-68
-
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OSL (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.8¢ |
Change
0.001(6.67%) |
Mkt cap ! $35.79M |
Open | High | Low | Value | Volume |
0.8¢ | 0.9¢ | 0.8¢ | $129.1K | 16.15M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
66 | 28947611 | 0.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.8¢ | 1719511 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 128380 | 0.008 |
66 | 28947611 | 0.007 |
25 | 9826065 | 0.006 |
17 | 15710198 | 0.005 |
9 | 9262824 | 0.004 |
Price($) | Vol. | No. |
---|---|---|
0.009 | 12908448 | 14 |
0.010 | 16816644 | 16 |
0.011 | 10154778 | 18 |
0.012 | 7560752 | 5 |
0.013 | 5349700 | 3 |
Last trade - 14.45pm 12/11/2024 (20 minute delay) ? |
Featured News
OSL (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online